Paul Rowe, MD, ATSF | Source | Vice President, Head of Global Medical, Immunology at Sanofi
Paul Rowe, MD, ATSF
Vice President, Head of Global Medical, Immunology at Sanofi
Bio
Edit
Dr. Rowe has over a decade of research experience spanning from pre-clinical to late phase drug development programs, primarily in respiratory medicine, at several large pharma companies. He has been directly responsible for lifecycle management of several COPD/asthma and cardiovascular therapies.
Recent Quotes
Sign up to view all
-
Dupixent has an effect on blocking the action of those cytokines. By blocking those cytokines we’re able to potentially also impact the inflammation and hence, have a chance at impacting those irreversible causes.
Media
Sign up to view all
-
AAD: Will Sanofi and Regeneron’s Dupixent be a game-changer or just another antibody on the COPD scrapheap?
Despite chronic obstructive pulmonary disease (COPD) being the world’s third most fatal disorder, treatment advances have been limited over the last decade.
Article
Employment
Sign up to view all
-
Sanofi (https://www.sanofi.com/)
Vice President, Head of Global Medical, Immunology
Popularity
Twitter Feed